Skip to content

Avivomed

1 viewer · 30d

Total raised

$5.0M

+$5.0M this year

1 filing since 2026 · latest Debt filed

Cumulative raised
LAST ROUND
Debt · $5.0M
ROUNDS
1
INVESTORS
7
FOUNDED
2021
HQ
Roseville, MN
SECTOR
Healthcare
EMPLOYEES
N/A
30D VIEWERS
1

AI overview

Updated

Avivomed is a Minnesota-based medical device company developing next-generation, minimally invasive neuromodulation therapies for obstructive sleep apnea (OSA). Its implantable systems stimulate nerves involved in maintaining an open upper airway during sleep, targeting the large share of OSA patients who cannot tolerate CPAP. The company was founded in 2021 and operates within the NuXcel innovation ecosystem. It is backed by F-Prime, Hatteras Venture Partners, Norwest, and Treo Ventures.

What sets it apart

A minimally invasive implantable neurostimulation approach positioned as an alternative for the up to 50% of obstructive sleep apnea patients who cannot tolerate CPAP, developed by a team with prior experience building implantable neuromodulation systems for hearing and sensory restoration.

Funding history

1 round
Debt+1Apr 16, 2026
Form D
+$5.0M$5.0M total

Latest SEC filings

via EDGAR · CIK 0001893991
Form D · Apr 16, 2026View on EDGAR

Products

1 tracked

Minimally invasive neuromodulation system for obstructive sleep apnea

Implantable medical device

An implantable neurostimulation system in development that delivers targeted nerve stimulation to help keep the upper airway open during sleep, treating obstructive sleep apnea without a mask or external airflow device.

  • Minimally invasive implantable design
  • Neuromodulation-based airway therapy delivered during sleep
  • Aimed at CPAP-intolerant obstructive sleep apnea patients
  • In development by a team with prior implantable neuromodulation experience

Links

WebsiteLinkedInSEC EDGAR filings